Skip to main content
Kemal Atlay on Muck Rack

Kemal Atlay

Verified
Sydney
As seen in: Australian Doctor, LinkedIn, Medium, The Guardian, News.com.au, New Zealand Herald, SBS, The New Daily, BODY + soul, Medical Observer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kemal

Contact Kemal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First subcutaneous immunotherapy for lung and liver cancers added to PBS

|
By Kemal Atlay Verified
| Australian Doctor Verified
Thousands of Australians with advanced lung and liver cancer can now access subsidised subcutaneous immunotherapy that cuts treatment time to seven minutes. On 1 August, Roche’s subcutaneous formulation of atezolizumab (Tecentriq SC) became the first such programmed death-ligand 1 immunotherapy on the PBS. × If this is your first visit to the new AusDoc website, reset your password here. Remember Me Forgot Password? Having trouble logging in? Back to sign in
Open in Who Shared Issue with article?

Medical Must-See: Lower back pain signals a rare, fatal cancer

|
By Kemal Atlay Verified
| Australian Doctor Verified
This Indonesian man’s lower back pain foreshadowed a more sinister diagnosis, with his doctors finding a rare, aggressive form of bone cancer infiltrating his soft tissue. The 50-year-old originally presented in 2021 with a six-month history of lower-left back pain that had gradually limited his activity. × If this is your first visit to the new AusDoc website, reset your password here. Remember Me Forgot Password? Having trouble logging in? Back to sign in
Open in Who Shared Issue with article?

Consider Shingrix for varicella-vaccinated patients: ATAGI proposal

|
By Kemal Atlay Verified
| Australian Doctor Verified
Adults who have received an indicated varicella vaccine should be eligible for the recombinant herpes zoster vaccine Shringrix, according to ATAGI. The Australian Immunisation Handbook currently recommends against administering both vaccines — except for in patients who have received a varicella vaccine against its indications. × If this is your first visit to the new AusDoc website, reset your password here. Remember Me Forgot Password? Having trouble logging in? Back to sign in
Open in Who Shared Issue with article?
See all 907 licensed articles (910 Total)